

Practitioner's Docket No. MPI00-513P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Kapeller-Libermann, Rosana		
Application No.:	10/017,216	Group No.:	1652
Filed:	October 23, 2001	Examiner:	MONSHIPOURI, MARYAM
For:	13245, A NOVEL HUMAN MYOTONIC DYSTROPHY TYPE PROTEIN KINASE AND USES THEREFOR		

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Confirmation No. 1141

TRANSMITTAL OF PAYMENT OF ISSUE FEE (37 C.F.R. SECTION 1.311)

1. Transmitted herewith for this application is/are:
 - a. This Transmittal Letter (2 pages – in duplicate);
 - b. PTOL-85 Part B – Fee(s) Transmittal (1 page - in duplicate);
 - c. Authorization to Act in a Representative Capacity (2 pages);
 - d. Statement of Limited Recognition under 37 CFR §11.9(b) for Mario Cloutier (1 page);
and
 - e. Return Postcard.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature



Sean Hunziker

(type or print name of person certifying)

Date: June 21, 2005

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

2. Applicant hereby pays the issue fee for the attached Issue Fee Transmittal PTOL-85.

3. **Fee** (37 C.F.R. Section 1.18(a)):

	<u>Regular</u>
Application status is other than a small entity--fee:	\$1,400.00
Publication Fee	\$300.00
Advance Order – patent copies (3)	\$9.00

4. **Payment of fee:**

Charge Account No. 501668 the sum of \$1,709.00. (A duplicate of this request is attached).
If any additional fee is required, charge Account No. 501668.

June 21, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By

Mario Cloutier

Mario Cloutier

Limited Recognition Under 37 C.F.R. §11.9(b)

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820



Practitioner's Docket No. MPI00-513P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Kapeller-Libermann, Rosana		
Continuation Application No.:	10/017,216	Group No.:	1652
Filed:	October 23, 2001	Examiner:	MONSHIPOURI, MARYAM
For:	13245, A NOVEL HUMAN MYOTONIC DYSTROPHY TYPE PROTEIN KINASE AND USES THEREFOR		

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier
Limited Recognition Under 37 CFR §11.9(b)
Customer Number 30405 or
Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature. _____

Sean Hunziker

(type or print name of person certifying)

Date: June 21, 2005

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

This is not a Power of Attorney to the above-named practitioner.

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

Please continue to forward all written and telephonic communications to Tracy M. Sioussat at the address and telephone number listed below.

SIGNATURE of Practitioner of Record

June 21, 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat

Tracy M. Sioussat

Attorney/Agent for Applicant

Reg. No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone: (617) 374-7679

Facsimile - (617) 551-8820




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 29, 2006



Harry I. Moatz
Director of Enrollment and Discipline